ZBIO Leon O. Moulder Jr. bought Zenas BioPharma, Inc. shares — SEC Form 4BUYZenas BioPharma, Inc.

ZBIO is trading at $16.895, having lost 36.89% over the last 90 days and 17.24% in the past five days. The stock remains significantly below its 52-week high of $44.60, down 62.12% from that peak.

• •Q1 2026 results reported on May 13, 2026, with a net loss of $80.99 million, setting the stage for the next earnings report.
• •$250 million non-dilutive loan secured on March 17, 2026, to support obexelimab commercialization.
• •Planned marketing applications for obexelimab in the U.S. and Europe mentioned in the March 17, 2026 news.

• •Short interest stands at 26.1% of the float, indicating significant bearish sentiment.
• •The company reported a Q1 2026 net loss of $80.99 million, a 141% increase from the prior year, raising concerns about cash burn.